University of Rostock, Department of Medicine, Division of Nephrology
Rostock, 18055, Germany
NCT Number: NCT00818597
The purpose of this study is to investigate the effect of an extracorporeal application of a bed-side bioreactor containing human donor granulocytes on the course and outcome of septic shock in humans.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Phase 1 / Phase 2
Rostock, 18055, Germany
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Two six hour-treatments with the EISS-Immune-cell bioreactor device within 72 hours post inclusion.
Time frame: 28day post inclusion
Time frame: 28day post inclusion
Looking for future studies?
Notify MeUniversity of Rostock
Other
PhaseI/II Study of the Safety and Efficacy of the Use of Granulocyte-Concentrates Applied in Extracorporeal Circulation Devices-the EISS-1 Study
Acronym: EISS-1
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02030158
Infections, Inflammation
View Trial DetailsNCT07819708
Infections, Inflammation
Banhā, Qalyubia Governorate, Egypt
View Trial DetailsNCT07786350
Infections, Inflammation
Medan, North Sumatra, Indonesia
View Trial DetailsNCT05725837
Infections, Inflammation
Colatina, Espírito Santo, Brazil
View Trial Details